Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans ...

The FDA released a much-anticipated draft guidance on how makers of rare disease genetic medicines can leverage a platform ...

Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 ...

The ABC's response to concerns it doctored Donald Trump's January 6 speech was dictated by the documentary's presenter Sarah Ferguson.